Safety of alemtuzumab in a nationwide cohort of Finnish multiple sclerosis patients

Ilkka Rauma, Tiina Mustonen, Juha Matti Seppä, Maritta Ukkonen, Marianne Männikkö, Auli Verkkoniemi-Ahola, Marge Kartau, Jukka T. Saarinen, Liisa Luostarinen, Sakari Simula, Mervi Ryytty, Riitta Ahmasalo, Jussi O.T. Sipilä, Ilkka Pieninkeroinen, Tero Tapiola, Anne M. Remes, Hanna Kuusisto

Tutkimustuotos: ArticleScientificvertaisarvioitu

1 Lataukset (Pure)

Abstrakti

Background: Alemtuzumab is an effective disease-modifying therapy (DMT) for highly active multiple sclerosis (MS). However, safety concerns limit its use in clinical practice. Objectives: To evaluate the safety of alemtuzumab in a nationwide cohort of Finnish MS patients. Methods: In this retrospective case series study, we analyzed the data of all but two MS patients who had received alemtuzumab in Finland until 2019. Data were systematically collected from patient files. Results: Altogether 121 patients were identified, most of whom had received previous DMTs (82.6%). Median follow-up time after treatment initiation was 30.3 months and exceeded 24 months in 78 patients. Infusion-associated reactions (IARs) were observed in 84.3%, 57.3%, and 57.1% of patients during alemtuzumab courses 1–3, respectively. Serious adverse events (SAEs) were observed in 32.2% of patients, serious IARs in 12.4% of patients, and SAEs other than IARs in 23.1% of patients. Autoimmune adverse events were observed in 30.6% of patients. One patient died of hemophagocytic lymphohistiocytosis, and one patient died of pneumonia. A previously unreported case of thrombotic thrombocytopenic purpura was documented. Conclusions: SAEs were more frequent in the present cohort than in previous studies. Even though alemtuzumab is a highly effective therapy for MS, vigorous monitoring with a long enough follow-up time is advised.

AlkuperäiskieliEnglanti
JulkaisuJournal of neurology
DOI - pysyväislinkit
TilaE-pub ahead of print - 13 heinäk. 2021
OKM-julkaisutyyppiA1 Alkuperäisartikkeli

Julkaisufoorumi-taso

  • Jufo-taso 1

!!ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Sormenjälki

Sukella tutkimusaiheisiin 'Safety of alemtuzumab in a nationwide cohort of Finnish multiple sclerosis patients'. Ne muodostavat yhdessä ainutlaatuisen sormenjäljen.

Siteeraa tätä